These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 32439327)
1. Intranasal delivery of tetrabenazine nanoemulsion via olfactory region for better treatment of hyperkinetic movement associated with Huntington's disease: Pharmacokinetic and brain delivery study. Arora A; Kumar S; Ali J; Baboota S Chem Phys Lipids; 2020 Aug; 230():104917. PubMed ID: 32439327 [TBL] [Abstract][Full Text] [Related]
2. An experimental model for Huntington's chorea? Zeef DH; Jahanshahi A; Vlamings R; Casaca-Carreira J; Santegoeds RG; Janssen ML; Oosterloo M; Temel Y Behav Brain Res; 2014 Apr; 262():31-4. PubMed ID: 24412685 [TBL] [Abstract][Full Text] [Related]
3. Design Expert(®) supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson's disease. Kumar S; Ali J; Baboota S Nanotechnology; 2016 Oct; 27(43):435101. PubMed ID: 27655136 [TBL] [Abstract][Full Text] [Related]
4. Intranasal delivery of insulin by self-emulsified nanoemulsion system: In vitro and in vivo studies. Shah D; Guo Y; Ban I; Shao J Int J Pharm; 2022 Mar; 616():121565. PubMed ID: 35150847 [TBL] [Abstract][Full Text] [Related]
5. Tetrabenazine in the treatment of hyperkinetic movement disorders. Kenney C; Jankovic J Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307 [TBL] [Abstract][Full Text] [Related]
6. CCRD based development of bromocriptine and glutathione nanoemulsion tailored ultrasonically for the combined anti-parkinson effect. Ashhar MU; Kumar S; Ali J; Baboota S Chem Phys Lipids; 2021 Mar; 235():105035. PubMed ID: 33400967 [TBL] [Abstract][Full Text] [Related]
7. Preparation, characterization, and optimization of asenapine maleate mucoadhesive nanoemulsion using Box-Behnken design: In vitro and in vivo studies for brain targeting. Kumbhar SA; Kokare CR; Shrivastava B; Gorain B; Choudhury H Int J Pharm; 2020 Aug; 586():119499. PubMed ID: 32505580 [TBL] [Abstract][Full Text] [Related]
8. Nanoemulsions for Intranasal Delivery of Riluzole to Improve Brain Bioavailability: Formulation Development and Pharmacokinetic Studies. Parikh RH; Patel RJ Curr Drug Deliv; 2016; 13(7):1130-1143. PubMed ID: 26638977 [TBL] [Abstract][Full Text] [Related]
9. Intranasal delivery of paroxetine nanoemulsion via the olfactory region for the management of depression: formulation, behavioural and biochemical estimation. Pandey YR; Kumar S; Gupta BK; Ali J; Baboota S Nanotechnology; 2016 Jan; 27(2):025102. PubMed ID: 26629830 [TBL] [Abstract][Full Text] [Related]
10. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. Koch J; Shi WX; Dashtipour K Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050 [TBL] [Abstract][Full Text] [Related]
11. The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route. Jiang Y; Liu C; Zhai W; Zhuang N; Han T; Ding Z Int J Nanomedicine; 2019; 14():9217-9234. PubMed ID: 31819426 [TBL] [Abstract][Full Text] [Related]
12. Brain targeted delivery of lurasidone HCl via nasal administration of mucoadhesive nanoemulsion formulation for the potential management of schizophrenia. Patel MR; Patel RB; Thakore SD; Solanki AB Pharm Dev Technol; 2020 Oct; 25(8):1018-1030. PubMed ID: 32432956 [TBL] [Abstract][Full Text] [Related]
13. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Mahajan HS; Mahajan MS; Nerkar PP; Agrawal A Drug Deliv; 2014 Mar; 21(2):148-54. PubMed ID: 24128122 [TBL] [Abstract][Full Text] [Related]
14. Kaempferol-loaded mucoadhesive nanoemulsion for intranasal administration reduces glioma growth in vitro. Colombo M; Figueiró F; de Fraga Dias A; Teixeira HF; Battastini AMO; Koester LS Int J Pharm; 2018 May; 543(1-2):214-223. PubMed ID: 29605695 [TBL] [Abstract][Full Text] [Related]
15. Development and optimization of nanoemulsion based gel for enhanced transdermal delivery of nitrendipine using box-behnken statistical design. Sharma A; Singh AP; Harikumar SL Drug Dev Ind Pharm; 2020 Feb; 46(2):329-342. PubMed ID: 31976777 [No Abstract] [Full Text] [Related]
16. Intranasal delivery of topiramate nanoemulsion: Pharmacodynamic, pharmacokinetic and brain uptake studies. Patel RJ; Parikh RH Int J Pharm; 2020 Jul; 585():119486. PubMed ID: 32502686 [TBL] [Abstract][Full Text] [Related]
17. Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. Bhatt R; Singh D; Prakash A; Mishra N Drug Deliv; 2015; 22(7):931-9. PubMed ID: 24512295 [TBL] [Abstract][Full Text] [Related]
18. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome. Paton DM Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387 [TBL] [Abstract][Full Text] [Related]
19. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Guay DR Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622 [TBL] [Abstract][Full Text] [Related]
20. Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose. Hasan N; Imran M; Kesharwani P; Khanna K; Karwasra R; Sharma N; Rawat S; Sharma D; Ahmad FJ; Jain GK; Bhatnagar A; Talegaonkar S Int J Pharm; 2021 Apr; 599():120428. PubMed ID: 33662465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]